MassDevice.com +5 | The top 5 medtech stories for December 13, 2016

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Defymed partners with Semma Therapeutics on bio-artificial pancreas French biotech developer Defymed said today it inked a collaborative deal with American biotech company Semma Therapeutics to support the continued development of a bio-artificial pancreas to treat type-1 diabetes. The collaborative deal will aim to achieve pre-clinical validation of Defymed’s Mailpan bio-artificial pancreas in combination with Semma’s stem-cell derived differentiated insulin-secreting cells, Defymed said. Read more 4. Boston Scientific fires neurmod patent infringement suit at Nevro in ongoing spat Nevro Corp. said last Friday that it received notice that Boston Scientific and its Neuromodulation division have filed a patent infringement suit against Nevro. The suit, filed in The United States District Court for the District of Delaware, claims Nevro’s Senza neuromodulation system infringes upon Boston Scientific patents covering stimulation leads, batteries and telemetry unit. Read more 3. Echo Therapeutics touts win in whistleblower case Echo Therapeutics this week announc...
Source: Mass Device - Category: Medical Equipment Authors: Tags: News Well Plus 5 Source Type: news